9 completed. 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 4 | Completed 4 |
Follow AVP-923: new trials by email Literature Review of AVP-923 trials Research Report on AVP-923
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants AVP-923 - Healthy Adult Male and Female Volunteers | Phase 1 | Completed | Avanir Pharmaceuticals | 17 | 2017-11-28 | 2018-02-23 |
| Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts AVP-923, AVP-786, Itraconazole - Healthy | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2015-03-01 | 2026-04-28 |
| A Phase 1 Study Comparing AVP-786 With AVP-923 AVP-786, AVP-923 - Healthy Volunteer | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 62 | 2014-05-01 | 2026-04-28 |
| A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers AVP-786, AVP-923 - Healthy | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 56 | 2013-09-01 | 2026-04-28 |
| Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers AVP-786 Dose 1, AVP-786 Dose 2, AVP-786 Dose 1/Q Dose 1 - Healthy | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 48 | 2012-10-01 | 2026-04-28 |
| Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo - Pseudobulbar Affect (PBA) | Phase 3 | Completed | Avanir Pharmaceuticals | 326 | 2007-12-01 | 2017-04-12 |
| Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) AVP-923 - Alzheimer's Disease, Stroke | Phase 3 | Completed | Avanir Pharmaceuticals | 600 | 2003-02-01 | 2016-07-14 |
| Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients AVP-923 - Multiple Sclerosis | Phase 3 | Completed | Avanir Pharmaceuticals | 96 | 2002-12-01 | 2016-07-14 |
| Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS AVP-923 - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Avanir Pharmaceuticals | 100 | 2001-01-01 | 2016-07-14 |
Amyotrophic Lateral Sclerosis (2) · Multiple Sclerosis (2) · Alzheimer Disease (1) · Brain Injuries, Traumatic (1) · Crying (1) · Laughter (1) · Parkinson Disease (1) · Stroke (1)
Avanir Pharmaceuticals (5) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4)
United States (7) · Australia (2) · Argentina (1) · Brazil (1)